Trial reportJournal of cosmetic dermatology2026
A Single-Center, Open-Label Study to Evaluate the Efficacy and Tolerability of Retinal Encapsulated in a Novel Biomimetic Exosome in the Treatment of Mild-To-Moderate Facial Photodamage.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNumerous retinoid-based skincare products are available over-the-counter for photodamaged and photoaged skin, but are associated with objective (e.g., erythema, dryness, flaking, edema) and subjective (e.g., itching, tingling, stinging, burning) tolerability issues. A novel retinal formulation was developed using an engineered biomimetic vegan exosome as a delivery system. The formulation also contains proprietary and potent hyaluronic acid, as well as plant-based actives commonly used in traditional herbal medicines for their anti-inflammatory and antioxidant properties.
aimsEvaluate the efficacy and tolerability of this biomimetic exosome-encapsulated retinal product for treatment of mild-to-moderate facial photodamage. PATIENTS/
methodsTwenty females aged 35 to 65 years, with Fitzpatrick skin types I-VI, mild-to-moderate facial fine lines and wrinkles, and mild-to-moderate facial photodamage, were assessed at screening/baseline and weeks 2, 4, 8, and 12. Investigator- and participant-assessed evaluations were performed at each visit. The primary objective was to demonstrate a decrease in the appearance of fine lines and wrinkles, erythema, as well as a reduction of overall facial photodamage after a 12-week topical regimen. The secondary objective was to measure the frequency of adverse events throughout the study.
resultsStatistically significant improvements in erythema, skin tone, skin texture, and lines/wrinkles were observed at all follow-up visits, compared to baseline. At weeks 8 and 12, all participants (100%) displayed improvements in facial aesthetics. Most participants (19/20; 95.00%) were satisfied with the product and would recommend it to others. No product-related adverse events were reported.
conclusionsDaily use of this "hydrating retinal" improved signs of facial photodamage with none to mild signs of skin irritation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.